InSilico Medicine Cayman TopCo (HKG:3696)

Revenue by Segment

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Biotechnology	85.83M	51.18M	30.15M
Biotechnology Growth	67.71%	69.77%	-
Total	85.83M	51.18M	30.15M
Total Growth	67.71%	69.77%	-

Revenue by Geography

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
United States	79.38M	45.91M	9.37M
United States Growth	72.93%	389.72%	-
Mainland China	2.14M	3.45M	9.24M
Mainland China Growth	-37.92%	-62.67%	-
Kingdom of Saudi Arabia	1.90M	-	-
United Kingdom	151.00K	46.00K	59.00K
United Kingdom Growth	228.26%	-22.03%	-
Hong Kong	28.00K	23.00K	10.01M
Hong Kong Growth	21.74%	-99.77%	-
Japan	699.00K	438.00K	207.00K
Japan Growth	59.59%	111.59%	-
United Arab Emirates	-	6.00K	-
Denmark	600.00K	270.00K	-
Denmark Growth	122.22%	-	-
Korea	284.00K	53.00K	2.00K
Korea Growth	435.85%	2550.00%	-
Germany	32.00K	93.00K	332.00K
Germany Growth	-65.59%	-71.99%	-
Switzerland	242.00K	655.00K	766.00K
Switzerland Growth	-63.05%	-14.49%	-
Taiwan	112.00K	34.00K	82.00K
Taiwan Growth	229.41%	-58.54%	-
Others	262.00K	209.00K	80.00K
Others Growth	25.36%	161.25%	-
Total	85.83M	51.18M	30.15M
Total Growth	67.71%	69.77%	-

Source: S&P Global Market Intelligence.